Compare Gilead Sciences, Inc. (GILD) vs Harley-Davidson Inc (HOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Harley-Davidson Inc — how do they compare? Gilead Sciences, Inc. trades at $147.95 (market cap $182.40B), while Harley-Davidson Inc trades at $27.04 (market cap $2.78B). The key difference: Gilead Sciences, Inc. is far larger — about 65.6× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays the higher dividend (2.8%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Harley-Davidson Inc for 91 Days on average.
| GILD | HOG | |
|---|---|---|
Market Cap | $182.40B | $2.78B |
Volume | 4,469,821 | 2,966,389 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $28.46 |
52-Week Low | $116.74 | $17.19 |
Typical Hold Time | 111 Days | 91 Days |
Enterprise Value | $205.46B | $3.20B |
Dividend Yield | 2.23% | 2.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Harley-Davidson (HOG) trades at $26.95, up 0.04% on the day, with a bullish technical signal and mixed earnings history. The company reported Q2 2026 EPS of $0.75, beating expectations, but revenue has declined from $5.8B in 2022 to $4.5B in 2025. Valuation ratios appear attractive with a P/E of 14.86 and P/B of 0.9, while analyst consensus is a hold with a $28.50 price target. Recent news includes a data breach investigation and a new product collaboration.
The outlook for HOG is cautious due to declining revenue and profit margins, offset by reasonable valuations and positive technical momentum. Key risks include tariff exposure, competitive pressures, and ongoing data security issues. Upside potential exists if the 'Back to the Bricks' strategy reverses sales trends, but investors should weigh fundamental weaknesses against technical strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →
